# OnCo record apollomics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/apollomics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "apollomics" ;
  schema:name "Apollomics"@en ;
  schema:alternateName "Apollomics Inc."@en, "Apollomics (Hangzhou)"@en ;
  schema:description "Apollomics is a US-Chinese company whose MET inhibitor vebreltinib is approved in China for MET exon 14 lung cancer through its partner Avistone, and whose E-selectin antagonist uproleselan failed in acute myeloid leukaemia in 2024."@en ;
  schema:url <https://onco.cc/companies/apollomics/>, <https://www.apollomicsinc.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.apollomicsinc.com>, <https://clinicaltrials.gov/search?lead=Apollomics> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/aml/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/met/> ;
  onco:drugs <https://onco.cc/drugs/vebreltinib/> ;
  onco:companies <https://onco.cc/companies/avistone-biotechnology/> ;
  onco:trials <https://onco.cc/trials/nct03175224/> .